Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announced the appointment of Dr. Cheung To as a Non-Executive Director with immediate effect.
Dr. Cheung To joins following Oncimmune’s licence agreement with Genostics Company Limited, announced in January 2018, when it was agreed that a representative from Genostics would be appointed to Oncimmune’s Board.
Dr. Cheung To is an entrepreneur with over 25 years’ of extensive experience in biotechnology research and instinctive knowledge of the development of the world’s, and China’s, biotechnology markets. He co-founded and is Chairman of Gene Group Co. Ltd., a group that now includes several major companies including: Gene Co. Ltd., one of the largest professional service and distribution provider for the medical, life science, pharmaceutical and biotech research sectors in China; Ecotek Co. Ltd., a professional services company to the agricultural and environmental research sectors in China; Genetech (Shanghai) Co. Ltd., a business focused on R&D, manufacturing, marketing & distribution of molecular and cellular diagnostic products in the fields of pathology, oncology, heamatology and molecular genetics; Ebiotrade.com, a Biotech portal and e-commerce provider; and Baygene Co. Ltd., a company focused on R&D, manufacturing and distribution of life-science research products.
Dr. Cheung To obtained his Ph.D from the University of Hong Kong, Medical Faculty, Dept. of Biochemistry in 1996, and he was awarded one of the experts in the prestige China’s National “Recruitment Program of Global Experts” (known as “the Thousand Talents Program”) in 2010, in recognition of his contribution towards the industries and society.
Meinhard Schmidt, Non-Executive Chairman of Oncimmune Holdings, commented: “I am delighted to welcome Dr. Cheung To to the Board. We have already established a strong working relationship while securing our framework and distribution agreement in China, and this has continued as we progress with the preparation for sales to commence. Dr. Cheung To’s track record speaks for itself and I look forward to drawing on his experience in developing and commercialising devices in China, a significant market for Oncimmune.”
Dr. Cheung To, Non-Executive Director of Oncimmune, commented: “I am excited by Oncimmune’s EarlyCDT® platform technology and its potential to significantly improve outcomes for cancer patients through early detection of disease and by enhancing the treatment pathway. I look forward to continuing to work with the Oncimmune team to maximise its potential more widely in China.”
